Evidence map›Paper›PMID 30851334›Full record

ArticleHuman pathology2019

TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Harsimar B Kaur, Jiayun Lu, Liana B Guedes, Laneisha Maldonado, Logan Reitz, John R Barber, Angelo M De Marzo, Scott A Tomlins, Karen S Sfanos, Mario Eisenberger and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Harsimar B KaurDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. Electronic address: hkaur14@jhmi.edu.
Jiayun LuDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Liana B GuedesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Laneisha MaldonadoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Logan ReitzDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
John R BarberDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Scott A TomlinsDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
Karen S SfanosDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Mario EisenbergerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Edward M SchaefferDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Northwestern University, Chicago, IL 60208, USA.
Corinne E JoshuDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Tamara L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Michigan–Ann Arbor · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236
6 · The paper itself

Abstract

The makeup of the tumor immune microenvironment may be associated with tumor somatic genomic alterations and plays a key role in tumor progression and response to immunotherapy. We examined the association of tumor-infiltrating T-cell density with TP53 status in surgically treated primary prostate cancer using 3 independent tissue microarray sets, including one set of tumors from grade-matched patients of European American or African American ancestry (n = 391), a retrospective case-cohort of intermediate- and high-risk patients enriched for adverse outcomes (n = 267), and a set of tumors with primary Gleason pattern 5 (n = 77). The presence of TP53 missense mutation, indicated by p53 nuclear accumulation using a genetically validated assay, was significantly associated with increased CD3+ T-cell density (median, 341 versus 231 CD3+ T cells/mm

Indexed as

Biomarkers, TumorHumansLymphocytes, Tumor-InfiltratingMaleMutation, MissenseNeoplasm GradingProstatic NeoplasmsRetrospective StudiesT-LymphocytesTumor Suppressor Protein p53Biomarkers, TumorTumor Suppressor Protein p53CD3CD8FOXP3Prostatic adenocarcinomaT cellsTP53Tumor-infiltrating lymphocytes

Identifiers

PMID30851334
PMCPMC8183670
OpenAlexW2920806235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.